The Future of Injectables: Subcutaneous DMPA (depo-subQ provera 104)
A new lower-dose formulation of DMPA, depo-subQ provera 104, is injected under the skin rather than in the muscle. Like the intramuscular formulation, depo-subQ provera is given at 3-month intervals. In developing countries it will be available in Uniject devices that are prefilled with the precise dosage of depo-subQ required for three months of contraceptive protection. Introduction of depo-subQ in Uniject provides opportunities to both strengthen clinic injection services and extend injectable contraceptive delivery safely and effectively beyond the clinic.
2011 | PATH | 6 pp
Depo-subQ in Uniject: Planning for Introduction
2011 | PATH | 2 pp
Project Summary (English) Project Summary (French) Clinical Brief (English) Clinical Brief (French)
A new formulation and presentation of Depo-Provera® will soon become available, offering the potential to create access for new users while improving continuation among existing users. This new version, known as depo-subQ provera 104™ in the Uniject®* device (depo-subQ in Uniject), contains 104 mg of depot medroxyprogesterone acetate (DMPA) and is administered via subcutaneous injection. The Uniject delivery system is a small, autodisable injection device that is prefilled with the precise dosage of depo-subQ required for three months of contraceptive protection.
Home-Based Administration of depo-subQ provera 104™ in the Uniject™ Injection System
2011 | PATH
Literature Review (English) Briefing Summary (English)
This literature review details the key findings on the feasibility and acceptability of home delivery of depo-subQ provera 104™ in the Uniject™ injection system (depo-subQ in Uniject). The review focused on self-injection and looked specifically at subcutaneous depot medroxyprogesterone acetate (DMPA) compared to the intramuscular formulation; considerations for home administration of injectable contraception, particularly in low-resource settings; and identified research needs for home administration, including self-injection, of depo-subQ in Uniject.
Logistics and Waste Management Benefits of Depo subQ in Uniject
2011 | PATH | 4 pp
English
This brief describes results from an analysis conducted by PATH comparing the current intramuscular version of depot medroxyprogesterone acetate (DMPA) injectable contraceptive compared with a new formulation packaged in the Uniject™ injection system. The analysis focused on waste management implications, identifying key quantitative and qualitative differences between the two products.
Injectables tomorrow: Subcutaneous DMPA and Home Injection (Population Reports)
2006 | Johns Hopkins Bloomberg School of Public Health/ Center for Communication Programs/ The INFO Project | 16 pp
New Study on Use of Injectable Contraceptives and HIV Risk
A new study published in The Lancet Infectious Diseases suggests that use of injectables may double the risk of uninfected women acquiring HIV and of HIV-infected women transmitting the virus to their uninfected partners.
For now, international health organizations and donors, including WHO, UNAIDS, and USAID, caution against making hasty changes to contraceptive policy or practice. (See also USAID's statement in French or Spanish.) WHO is convening a Technical Consultation from 31 January to 1 February 2012 to examine all evidence related to the potential effects of hormonal contraception on HIV acquisition, transmission, and disease progression, and will decide whether modifications need to be made to current WHO guidance. [read more]
Toolkit last updated: 27 January 2012
The information provided on this website is not official U.S. Government information and does not represent the views or position
of the U.S. Agency for International Development, the U.S. Government, or The Johns Hopkins University. Read our full Security & Privacy Policies.